(-)-Epicatechin and Pulmonary Arterial Hypertension
Primary Purpose
Pulmonary Arterial Hypertension
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
(-)-Epicatechin
Sponsored by
About this trial
This is an interventional treatment trial for Pulmonary Arterial Hypertension focused on measuring PAH
Eligibility Criteria
Inclusion Criteria:
- Male or female age 18 or older
- NYHA Class II-!V
- 6 minute walk distance < 450 meters
- Outpatients with suspected WHO group I PAH or and established diagnosis of WHO group I PAH undergoing clinically indicated right heart catheterization
- Written informed consent obtained from subject and ability for subject to comply with the requirements of study
Exclusion Criteria:
- Pregnancy
- Breast feeding
- Systolic blood pressure <100 or >160
- History of migraine headaches
- Allergy or intolerance to chocolate, tea or wine
- Subject is considered unsuitable for the study in the opinion of the investigator, nurse practitioner, or study physician for any other reason
Sites / Locations
- UCSF
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
(-)-Epicatechin
Arm Description
A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
Outcomes
Primary Outcome Measures
Pulmonary Vascular Resistance Index
This study will assess acute hemodynamic effects, specifically effects on pulmonary vascular resistance index (PVRI), of a single dose of purified (-)-epicatechin in patients with patients with PAH.
Secondary Outcome Measures
Endothelial function and hemodynamics
Secondary objectives are to determine if endothelial function, right heart function, nitric oxide and mitochondrial function improve following consumption of purified (-)-epicatechin.
Full Information
NCT ID
NCT01880866
First Posted
May 28, 2013
Last Updated
September 9, 2014
Sponsor
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT01880866
Brief Title
(-)-Epicatechin and Pulmonary Arterial Hypertension
Official Title
An Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Withdrawn
Study Start Date
July 2013 (undefined)
Primary Completion Date
January 2014 (Anticipated)
Study Completion Date
January 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Pulmonary arterial hypertension (PAH) is a progressive disease that results in severe activity limitation and death. There are few treatments for PAH and the available medications are expensive, difficult to administer and have significant toxicities.
(-)-Epicatechin is a non-toxic compound that naturally occurs in foods such as tea, wine and chocolate. Clinical intervention studies using dark chocolate in normal volunteers and subjects at risk for or with established cardiovascular disease have demonstrated improvements in peripheral and coronary vascular endothelial function, blood pressure, lipids, glucose tolerance and inflammatory markers.
Our study intends to examine the hemodynamics effects of purified (-)-epicatechin in subjects with pulmonary arterial hypertension. We hypothesize purified (-)-epicatechin will reduce pulmonary vascular resistance in patients with pulmonary arterial hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Arterial Hypertension
Keywords
PAH
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
(-)-Epicatechin
Arm Type
Experimental
Arm Description
A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
Intervention Type
Drug
Intervention Name(s)
(-)-Epicatechin
Intervention Description
A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
Primary Outcome Measure Information:
Title
Pulmonary Vascular Resistance Index
Description
This study will assess acute hemodynamic effects, specifically effects on pulmonary vascular resistance index (PVRI), of a single dose of purified (-)-epicatechin in patients with patients with PAH.
Time Frame
up to 5 hours after right heart catheterization
Secondary Outcome Measure Information:
Title
Endothelial function and hemodynamics
Description
Secondary objectives are to determine if endothelial function, right heart function, nitric oxide and mitochondrial function improve following consumption of purified (-)-epicatechin.
Time Frame
up to 5 hours after right heart catheterization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female age 18 or older
NYHA Class II-!V
6 minute walk distance < 450 meters
Outpatients with suspected WHO group I PAH or and established diagnosis of WHO group I PAH undergoing clinically indicated right heart catheterization
Written informed consent obtained from subject and ability for subject to comply with the requirements of study
Exclusion Criteria:
Pregnancy
Breast feeding
Systolic blood pressure <100 or >160
History of migraine headaches
Allergy or intolerance to chocolate, tea or wine
Subject is considered unsuitable for the study in the opinion of the investigator, nurse practitioner, or study physician for any other reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher Barnett, MD, MPH
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF
City
San Francisco
State/Province
California
ZIP/Postal Code
94110
Country
United States
12. IPD Sharing Statement
Learn more about this trial
(-)-Epicatechin and Pulmonary Arterial Hypertension
We'll reach out to this number within 24 hrs